Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 5/20 | 0.64 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.60 |
| ▸ | IDO1 | P14902 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10154007 | 0.86 | PKM (0.67) | PKMIDO1ALDH1A1 | |
| SCHEMBL30437651 | 0.84 | SMYD3 (0.64) | PKMSMYD3IDO1TDP1MAPT | |
| SCHEMBL687482 | 0.84 | PKM (0.60) | PKMSMYD3IDO1TDP1MAPT | |
| SCHEMBL4221206 | 0.84 | BRD4 (0.66) | PKMSMYD3IDO1TDP1MAPT | |
| SCHEMBL1556955 | 0.82 | GAA (0.60) | PKMSMYD3IDO1TDP1MAPT | |
| SCHEMBL4896390 | 0.81 | PKM (0.57) | PKMSMYD3IDO1TDP1MAPT | |
| SCHEMBL5843084 | 0.81 | SMYD3 (0.88) | PKMSMYD3IDO1TDP1MAPT | |
| SCHEMBL4408806 | 0.80 | PKM (0.69) | PKMIDO1TDP1MAPTGAA | |
| SCHEMBL6602558 | 0.79 | GAA (0.57) | PKMSMYD3IDO1TDP1MAPT | |
| SCHEMBL517067 | 0.79 | GAA (0.60) | PKMSMYD3IDO1TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2004-07-29 | — | — | US | claimed |
| EP-1294688-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2003-03-26 | — | — | EP | claimed |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2002-05-02 | — | — | US | claimed |
| US-20020026053-A1 | Novel 3-(substituted) -2- indolinones compounds and use thereof as inhibitors of protein kinase activity | TANG PENG CHO (US) | 2002-02-28 | — | — | US | claimed |
| WO-2001094312-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-12-13 | — | — | WO | claimed |
| US-20010007033-A1 | Novel 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity | SUGEN, INC. | 2001-07-05 | — | — | US | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| EP-4562010-A1 | CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR | Novartis AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| US-20240141022-A1 | ANTIBODY-CYTOKINS ENGRAFTED PROTEINS AND METHODS OF US IN THE TREATMENT OF CANCER | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2024-05-02 | — | — | US | disclosed |
| WO-2024023666-A1 | CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR | NOVARTIS AG (CH) | 2024-02-01 | — | — | WO | disclosed |
| CN-116096426-A | CCR7 antibody drug conjugates for the treatment of cancer | 诺华股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4142799-A1 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | Novartis AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| EP-4076660-A1 | USES OF ANTI-TGF-BETA ANTIBODIES AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2022-10-26 | — | — | EP | disclosed |
| EP-0984930-A1 | 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY | Sugen, Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999061422-A1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
| EP-0912557-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998050356-A1 | 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY | SUGEN, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1997042187-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020026053-A1 | Novel 3-(substituted) -2- indolinones compounds and use thereof as inhibitors of protein kinase activity | MAP3K20, SBK3, MAP4K2 | PKM 504/4885SMYD3 3221/4885IDO1 776/4885 |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | PKM 1794/4885SMYD3 1606/4885IDO1 3911/4885 |
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | PKM 246/4885SMYD3 2338/4885IDO1 584/4885 |
| US-20010007033-A1 | Novel 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity | SBK3, MAP4K2, MAP3K20 | PKM 496/4885SMYD3 3251/4885IDO1 815/4885 |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | PKM 246/4885SMYD3 2338/4885IDO1 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.